Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

IGFBP-1 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Insulin-Like Growth Factor Binding Protein-1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RMEE01 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Cell culture medium, Urine, Amniotic fluid, Milk, Saliva

Sample Requirements

20 μl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0–8 ng/ml

Limit of Detection

0.02 ng/ml

Summary

Features

  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!

Research topic

Growth hormone and factor-related products

Summary

Insulin-like growth factor binding protein-1 (IGFBP-1) is one of six proteins that specifically bind insulin-like growth factors I and II (IGF-I and IGF-II) in body fluids and tissues. IFGBP-1 contains 234 amino acids, with a predicted molecular mass of 25 kDa. The major sites of IGFBP-1 synthesis are the fetal /adult liver and decidualized endometrium. Serum levels of IGFBP-1, which reflect its synthesis by the liver, exhibit considerable diurnal variation. Circulating IGFBP-1 levels are highest early in the morning and lowest in the evening. The levels are high in the fetus and newborn, but decline steadily until puberty. The mean level of IGFBP-1 in healthy adults is 4.4 μg/L (range 0.6–14.4 μg/L). After about 65 years of age, serum IGFBP-1 levels begin to increase. There is also an inverse correlation between body mass index (BMI) and fasting serum IGFBP-1 concentrations. The most important regulator of circulating IGFBP-1 is insulin. Fasting insulin and IGFBP-1 concentrations are inversely correlated. During a 3-h glucose tolerance test, there is a decrease of about 50% in serum IFGBP-1 levels. Eating a meal also has a decreasing effect. In insulin-dependent diabetes (IDDM), serum IGFBP-1 levels are elevated. In non-insulin dependent diabetes, in which insulin levels are high, serum IGFBP-1 is decreased. Low levels of IGFBP-1 have also been observed in the following cases: acromegaly, Cushing’s syndrome and polysystic ovarian syndrome (PCO).

References to Summary

References to IGFBP-1

  • Lockwood CJ, Wein R, Chien D, Ghidini A, Alvarez M, Berkowitz RL. Fetal membrane rupture is associated with the presence of insulin-like growth factor-binding protein-1 in vaginal secretions. Am J Obstet Gynecol. 1994 Jul;171 (1):146-50
  • Lockwood CJ, Wein R, Chien D, Ghidini A, Alvarez M, Berkowitz RL. Fetal membrane rupture is associated with the presence of insulin-like growth factor-binding protein-1 in vaginal secretions. Am J Obstet Gynecol. 1994 Jul;171 (1):146-50
  • Rutanen EM. Insulin-Like Growth Factor Binding Protein-1 (Review) Seminars in Reprod. Endocrinol. 10:154-163, 1992;
  • Rutanen EM, Karkkainen T, Stenman UH, Yki-Jarvinen H. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab. 1993 Nov;77 (5):1152-5
  • Rutanen EM, Pekonen F, Karkkainen T. Measurement of insulin-like growth factor binding protein-1 in cervical/vaginal secretions: comparison with the ROM-check Membrane Immunoassay in the diagnosis of ruptured fetal membranes. Clin Chim Acta. 1993 Jan 31;214 (1):73-81
  • Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab. 1993 Jul;77 (1):199-204
Related Products Documents